Tenaya Therapeutics
TNYA
47 hedge funds and large institutions have $693M invested in Tenaya Therapeutics in 2021 Q3 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
82% more ownership
Funds ownership: 0% → 82% (+82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
+$202M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$110M |
| 3 |
CC
Casdin Capital
New York
|
+$77.1M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$76.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$59.6M |
Top Sellers
TNYA Hedge Fund Activity: Q3 2021 in Review
47 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q3 2021, worth a combined $693M.
Buyers outnumbered sellers: 47 funds opened new TNYA positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Column Group, opening a new position worth an estimated $202M.
- 47 institutional investors held Tenaya Therapeutics (TNYA) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $693M of Tenaya Therapeutics stock for Q3 2021.
- 47 funds opened new Tenaya Therapeutics positions in Q3 2021 and 0 closed out, a net change of +47 holders.
- The largest Tenaya Therapeutics buyer in Q3 2021 was Column Group, an estimated $202M added.
Based on aggregated 13F filings for Q3 2021.